Prognostic value of the 21-gene recurrence score in ER-positive,HER2-negative,node-positive breast c

• 作 者: Jiayi Wu Weiqi Gao Xiaosong Chen Chunxiao Fei Lin Lin Weiguo Chen Ou Huang Siji Zhu Jianrong He Yafen Li Li Zhu Kunwei Shen
• 机 构: Comprehensive Breast Health Center,Ruijin Hospital Affiliated to Shanghai Jiao Tong University Schoo
• 出 处: 医学前沿
• 发表日期: 2021年4期
• 关键词: early breast cancer 21-gene assay recurrence score prognosis

Multi-gene assays have emerged as crucial tools for risk stratification in early-stage breast cancer.This study aimed to evaluate the prognostic significance of the 21-gene recurrence score(RS)in Chinese patients with pN0-1,estrogen receptor-positive(ER+),human epidermal growth factor receptor 2-negative(HER2-)breast cancer.Among 800 patients recruited between 2009 and 2016,the median RS was 24(0-69),with 27.4％,46.8％,and 25.9％patients classified into low-,intermediate-,and high-risk groups.Cox regression analysis demonstrated that the high-risk category was associated with significantly higher odds of invasive disease-free survival(IDFS)and distant disease-free survival(DDFS)events compared with the low-risk category(IDFS:HR=2.450,95％CI 1.017-5.902,P=0.046;DDFS:HR=2.829,95％CI 1.013-7.901,P=0.047).No significant association between RS category and overall survival(OS)was found(intermediate vs.low:HR=1.244,95％CI 0.292-5.297,P=0.768;high vs.low:HR=2.933,95％CI 0.759-11.327,P=0.119).RS,as a continuous variable,was a highly significant predictor for IDFS(HR=1.028,95％CI 1.010-1.047,P=0.002),DDFS(HR=1.030,95％CI 1.010-1.051,P=0.003),and OS(HR=1.034,95％CI 1.007-1.063,P=0.014).Our findings suggested that RS may predict IDFS in Chinese patients with ER+/HER2-breast cancer with N0 or N1 disease.